Closure Q2
This article was originally published in The Tan Sheet
Executive Summary
Manufacturer of J&J/Ethicon Liquid Band-Aid anticipates flat year-over-year sales for the wound care product, citing pricing pressures and competition from 3M's Nexcare Liquid Bandage. In response, J&J has launched pricing and promotional initiatives in the last month, Closure notes during a second quarter earnings call July 22. Despite difficulties in the U.S. market, Closure reported strong international results for its consumer business, which helped drive a 33% increase in consolidated sales to $11.3 mil. Earnings were $2.5 mil., up 52%...
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.